We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
10x Genomics & Fred Hutch Join Forces on Cancer Biomarker Research
Read MoreHide Full Article
Key Takeaways
10x Genomics partners with Fred Hutch to advance biomarker discovery in bladder cancer and AML detection.
TXG will use Flex Apex and Xenium to study tumor biology and identify markers linked to treatment response.
The collaboration aims to improve AML residual disease detection and expand clinical use of 10x's platforms.
10x Genomics, Inc. (TXG - Free Report) recently announced a multi-project research collaboration with Fred Hutchinson Cancer Center to advance single-cell and spatial technologies across solid tumors and blood cancers. The collaboration will focus on biomarker discovery in advanced bladder cancer and residual disease detection in acute myeloid leukemia (AML), marking 10x Genomics’ first clinical research initiative extending into hematologic malignancies.
Per management, cancer care has more effective therapies than ever, but there remains a significant need to better identify which treatments will benefit individual patients. 10x Genomics believes single-cell and spatial biology can provide direct insights into the biology that drives treatment response in tumors and blood, supporting the advancement of precision oncology.
TXG Stock Trend Following the News
Following the announcement, TXG stock lost 5.6% at yesterday’s close. Year to date, the stock skyrocketed 366.6%, outperforming the industry’s 15.9% growth and the S&P 500’s 14.5% gain.
The collaboration could strengthen TXG’s long-term growth opportunity by expanding the use of its technology into clinically relevant applications where precise biological information may improve treatment decisions. Successful research outcomes could increase demand for 10x’s platforms among cancer centers and pharmaceutical researchers while creating additional opportunities for biomarker development and clinical testing. The initiative may also help demonstrate the commercial value of TXG’s technology beyond traditional research applications.
TXG currently has a market capitalization of $10.51 billion.
Image Source: Zacks Investment Research
More on the News
The bladder cancer project will use TXG’s Flex Apex and Xenium platforms, with plans to incorporate Atera, to examine tumor samples from patients receiving antibody-drug conjugates, immune checkpoint inhibitors and other therapies. Researchers will evaluate drug-target expression and tumor-microenvironment characteristics to identify biological markers associated with treatment response and clinical outcomes.
A second project will investigate whether Flex Apex-based single cell analysis can improve residual disease detection in AML. Current monitoring relies on multiple technologies, creating an opportunity for an integrated approach to identifying residual leukemic cells following treatment.
The collaboration also supports 10x Genomics’ broader efforts to build evidence for clinical applications of its single-cell and spatial technologies. Together with the company’s planned CLIA-certified laboratory, the initiative is expected to contribute to a framework for clinical reporting and help define how cellular and spatial data could support treatment planning in oncology and autoimmune disease.
Industry Prospects Favoring the Market
Going by the data provided by Grandview Research, the global single-cell analysis market is estimated to reach $6.5 billion in 2026 and is projected to witness a CAGR of 21.7% through 2033.
Factors like the growing number of drug discovery activities, technological advancements in genomics and cell analysis tools, and rising demand for precision medicine and oncology research are boosting the market’s growth.
Other News
10x Genomics recently announced Sentira, a new cloud-based computational platform designed to simplify and accelerate analysis of single-cell and spatial biology data. Its Sentira Spatial Analysis uses NVIDIA-accelerated computing to reduce processing times from hours to minutes. The platform is currently in early access and is expected to launch commercially in early 2027.
10x Genomics recently began commercial shipments of Atera, its next-generation spatial biology platform designed to combine whole-transcriptome analysis, sub-cellular resolution and single-cell sensitivity at scale. Demand for Atera has exceeded the company’s initial 2026 shipment expectations, with booked orders surpassing 40 instruments.
Currently, 10x Genomics carries a Zacks Rank #3 (Hold).
Some better-ranked stocks from the broader medical space are OPKO Health (OPK - Free Report) , Globus Medical (GMED - Free Report) and Merit Medical Systems (MMSI - Free Report) .
OPKO Health, currently flaunting a Zacks Rank #1 (Strong Buy), reported a second-quarter 2026 adjusted loss of 1 cent per share, which surpassed the Zacks Consensus Estimate by 87.5%. Revenues of $163.6 million beat the Zacks Consensus Estimate by 24.7%. You can see the complete list of today’s Zacks #1 Rank stocks here.
OPK has an estimated earnings growth rate of 23.3% for 2026. The company’s earnings beat estimates in each of the trailing four quarters, the average surprise being 95.1%.
Globus Medical, currently carrying a Zacks Rank #2 (Buy), reported a second-quarter 2026 adjusted EPS of $1.34, which surpassed the Zacks Consensus Estimate by 19.6%. Revenues of $789.6 million beat the Zacks Consensus Estimate by 0.4%.
GMED has an estimated long-term earnings growth rate of 12.4%. The company’s earnings beat estimates in each of the trailing four quarters, the average surprise being 27.9%.
Merit Medical Systems, carrying a Zacks Rank #2 at present, reported second-quarter 2026 adjusted EPS of $1.19, which beat the Zacks Consensus Estimate by 23.9%. Revenues of $418.8 million surpassed the Zacks Consensus Estimate by 3.5%.
MMSI has an estimated long-term earnings growth rate of 10.4%. MMSI’s earnings surpassed estimates in the trailing four quarters, the average surprise being 14.1%.
View the Zacks #1 Rank List
Image: Bigstock
10x Genomics & Fred Hutch Join Forces on Cancer Biomarker Research
Key Takeaways
10x Genomics, Inc. (TXG - Free Report) recently announced a multi-project research collaboration with Fred Hutchinson Cancer Center to advance single-cell and spatial technologies across solid tumors and blood cancers. The collaboration will focus on biomarker discovery in advanced bladder cancer and residual disease detection in acute myeloid leukemia (AML), marking 10x Genomics’ first clinical research initiative extending into hematologic malignancies.
Per management, cancer care has more effective therapies than ever, but there remains a significant need to better identify which treatments will benefit individual patients. 10x Genomics believes single-cell and spatial biology can provide direct insights into the biology that drives treatment response in tumors and blood, supporting the advancement of precision oncology.
TXG Stock Trend Following the News
Following the announcement, TXG stock lost 5.6% at yesterday’s close. Year to date, the stock skyrocketed 366.6%, outperforming the industry’s 15.9% growth and the S&P 500’s 14.5% gain.
The collaboration could strengthen TXG’s long-term growth opportunity by expanding the use of its technology into clinically relevant applications where precise biological information may improve treatment decisions. Successful research outcomes could increase demand for 10x’s platforms among cancer centers and pharmaceutical researchers while creating additional opportunities for biomarker development and clinical testing. The initiative may also help demonstrate the commercial value of TXG’s technology beyond traditional research applications.
TXG currently has a market capitalization of $10.51 billion.
Image Source: Zacks Investment Research
More on the News
The bladder cancer project will use TXG’s Flex Apex and Xenium platforms, with plans to incorporate Atera, to examine tumor samples from patients receiving antibody-drug conjugates, immune checkpoint inhibitors and other therapies. Researchers will evaluate drug-target expression and tumor-microenvironment characteristics to identify biological markers associated with treatment response and clinical outcomes.
A second project will investigate whether Flex Apex-based single cell analysis can improve residual disease detection in AML. Current monitoring relies on multiple technologies, creating an opportunity for an integrated approach to identifying residual leukemic cells following treatment.
The collaboration also supports 10x Genomics’ broader efforts to build evidence for clinical applications of its single-cell and spatial technologies. Together with the company’s planned CLIA-certified laboratory, the initiative is expected to contribute to a framework for clinical reporting and help define how cellular and spatial data could support treatment planning in oncology and autoimmune disease.
Industry Prospects Favoring the Market
Going by the data provided by Grandview Research, the global single-cell analysis market is estimated to reach $6.5 billion in 2026 and is projected to witness a CAGR of 21.7% through 2033.
Factors like the growing number of drug discovery activities, technological advancements in genomics and cell analysis tools, and rising demand for precision medicine and oncology research are boosting the market’s growth.
Other News
10x Genomics recently announced Sentira, a new cloud-based computational platform designed to simplify and accelerate analysis of single-cell and spatial biology data. Its Sentira Spatial Analysis uses NVIDIA-accelerated computing to reduce processing times from hours to minutes. The platform is currently in early access and is expected to launch commercially in early 2027.
10x Genomics recently began commercial shipments of Atera, its next-generation spatial biology platform designed to combine whole-transcriptome analysis, sub-cellular resolution and single-cell sensitivity at scale. Demand for Atera has exceeded the company’s initial 2026 shipment expectations, with booked orders surpassing 40 instruments.
10x Genomics Price
10x Genomics price | 10x Genomics Quote
TXG’s Zacks Rank & Key Picks
Currently, 10x Genomics carries a Zacks Rank #3 (Hold).
Some better-ranked stocks from the broader medical space are OPKO Health (OPK - Free Report) , Globus Medical (GMED - Free Report) and Merit Medical Systems (MMSI - Free Report) .
OPKO Health, currently flaunting a Zacks Rank #1 (Strong Buy), reported a second-quarter 2026 adjusted loss of 1 cent per share, which surpassed the Zacks Consensus Estimate by 87.5%. Revenues of $163.6 million beat the Zacks Consensus Estimate by 24.7%. You can see the complete list of today’s Zacks #1 Rank stocks here.
OPK has an estimated earnings growth rate of 23.3% for 2026. The company’s earnings beat estimates in each of the trailing four quarters, the average surprise being 95.1%.
Globus Medical, currently carrying a Zacks Rank #2 (Buy), reported a second-quarter 2026 adjusted EPS of $1.34, which surpassed the Zacks Consensus Estimate by 19.6%. Revenues of $789.6 million beat the Zacks Consensus Estimate by 0.4%.
GMED has an estimated long-term earnings growth rate of 12.4%. The company’s earnings beat estimates in each of the trailing four quarters, the average surprise being 27.9%.
Merit Medical Systems, carrying a Zacks Rank #2 at present, reported second-quarter 2026 adjusted EPS of $1.19, which beat the Zacks Consensus Estimate by 23.9%. Revenues of $418.8 million surpassed the Zacks Consensus Estimate by 3.5%.
MMSI has an estimated long-term earnings growth rate of 10.4%. MMSI’s earnings surpassed estimates in the trailing four quarters, the average surprise being 14.1%.